Central visual field damage in glaucoma eyes with choroidal microvasculature dropout with and without high axial myopia.

Autor:	Micheletti E; Department of Ophthalmology at the Shiley Eye Institute, University of California at San Diego, La Jolla, California, USA., El-Nimri N; Department of Ophthalmology at the Shiley Eye Institute, University of California at San Diego, La Jolla, California, USA., Nishida T; Department of Ophthalmology at the Shiley Eye Institute, University of California at San Diego, La Jolla, California, USA., Moghimi S; Department of Ophthalmology at the Shiley Eye Institute, University of California at San Diego, La Jolla, California, USA., Rezapour J; Department of Ophthalmology at the Shiley Eye Institute, University of California at San Diego, La Jolla, California, USA.; Department of Ophthalmology, University Medical Center of the Johannes Gutenberg University Mainz, Mainz, Germany., Fazio MA; Department of Ophthalmology at the Shiley Eye Institute, University of California at San Diego, La Jolla, California, USA.; Department of Ophthalmology and Visual Sciences, University of Alabama at Birmingham, Birmingham, Alabama, USA., Suh MH; Department of Ophthalmology at the Shiley Eye Institute, University of California at San Diego, La Jolla, California, USA.; Department of Ophthalmology, Inje University Busan Paik Hospital, Busan, Korea (the Republic of)., Bowd C; Department of Ophthalmology at the Shiley Eye Institute, University of California at San Diego, La Jolla, California, USA., Belghith A; Department of Ophthalmology at the Shiley Eye Institute, University of California at San Diego, La Jolla, California, USA., Christopher M; Department of Ophthalmology at the Shiley Eye Institute, University of California at San Diego, La Jolla, California, USA., Jonas JB; Department of Ophthalmology, University of Heidelberg Faculty of Medicine Mannheim Institute of Public Health, Mannheim, Germany., Weinreb RN; Department of Ophthalmology at the Shiley Eye Institute, University of California at San Diego, La Jolla, California, USA., Zangwill LM; Department of Ophthalmology at the Shiley Eye Institute, University of California at San Diego, La Jolla, California, USA lzangwill@ucsd.edu.
Jazyk:	angličtina
Zdroj:	The British journal of ophthalmology [Br J Ophthalmol] 2024 Feb 21; Vol. 108 (3), pp. 372-379. Date of Electronic Publication: 2024 Feb 21.
DOI:	10.1136/bjo-2022-322234
Abstrakt:	Purpose: To characterise the relationship between a deep-layer microvasculature dropout (MvD) and central visual field (VF) damage in primary open-angle glaucoma (POAG) patients with and without high axial myopia. Design: Cross-sectional study. Methods: Seventy-one eyes (49 patients) with high axial myopia and POAG and 125 non-highly myopic POAG eyes (97 patients) were enrolled. Presence, area and angular circumference of juxtapapillary MvD were evaluated on optical coherence tomography angiography B-scans and en-face choroidal images. Results: Juxtapapillary MvD was detected more often in the highly myopic POAG eyes (43 eyes, 86%) than in the non-highly myopic eyes (73 eyes, 61.9%; p=0.002). In eyes with MvD, MvD area and angular circumference (95% CI) were significantly larger in the highly myopic eyes compared with the non-highly myopic eyes (area: (0.69 (0.40, 0.98) mm 2 vs 0.31 (0.19, 0.42) mm 2 , p=0.011) and (angular circumference: 84.3 (62.9, 105.8) vs 74.5 (58.3, 90.9) degrees, p<0.001), respectively. 24-2 VF mean deviation (MD) was significantly worse in eyes with MvD compared with eyes without MvD in both groups (p<0.001). After adjusting for 24-2 MD VF, central VF defects were more frequently found in eyes with MvD compared with eyes without MvD (82.7% vs 60.9%, p<0.001). In multivariable analysis, higher intraocular pressure, worse 24-2 VF MD, longer axial length and greater MvD area and angular circumference were associated with worse 10-2 VF MD. Conclusions: MvD was more prevalent and larger in POAG eyes with high myopia than in non-highly myopic POAG eyes. In both groups, eyes with MvD showed worse glaucoma severity and more central VF defects. Competing Interests: Competing interests: Financial disclosures: EM: none; NE-N: none; TN: none; SM: none; JR: none; MAF: National Eye Institute (F), Heidelberg Engineering (F), Topcon (F); MHS: none; CB: none; AB: none; MC: none; JBJ: European patent EP 3 271 392, JP 2021-119187 and US 2021 0340237 A1: agents for use in the therapeutic or prophylactic treatment of myopia or hyperopia; RW: Abbvie (C), Alcon (C), Amydis (C), Eyenovia (C), Topcon (C), Nicox (C), Topcon (C), Heidelberg Engineering (F), Implandata (C), IOPtic (C), Carl Zeiss Meditec (F), Konan Medical (F), OptoVue (F), Topcon (F), Centervue (F), National Eye Institute (F), National Institute of Minority Health (F); LMZ: National Eye Institute (F), Carl Zeiss Meditec Inc. (F), Heidelberg Engineering GmbH (F), OptoVue Inc. (F, R), Topcon Medical Systems Inc (F, R) and Abbvie (C). (© Author(s) (or their employer(s)) 2024. No commercial re-use. See rights and permissions. Published by BMJ.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu